[{"id":"e87af69a-d323-4381-8103-c49ab9c91458","acronym":"","url":"https://clinicaltrials.gov/study/NCT06934538","created_at":"2025-07-12T13:49:40.870Z","updated_at":"2025-07-12T13:49:40.870Z","phase":"Phase 1/2","brief_title":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06934538","lead_sponsor":"Brenus Pharma","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • cyclophosphamide • oxaliplatin • STC-1010"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-07-11"},{"id":"1eccb30a-8ad1-4c26-a948-9dcc1f4fa1f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03832855","created_at":"2021-01-18T18:55:29.583Z","updated_at":"2025-02-25T12:27:07.330Z","phase":"Phase 1","brief_title":"Assessing the Immunogenicity of pING-hHER3FL","source_id_and_acronym":"NCT03832855","lead_sponsor":"Herbert Lyerly","biomarkers":" ERBB3","pipe":" | ","alterations":" ERBB3 expression","tags":["ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pING-hHER3FL"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-24"},{"id":"1f7645ce-b871-4582-a76b-ca5622eeebeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05419011","created_at":"2022-06-15T16:54:47.107Z","updated_at":"2025-02-25T13:41:05.612Z","phase":"Phase 2","brief_title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","source_id_and_acronym":"NCT05419011","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":"","alterations":" ","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-21"},{"id":"668fd5a3-2595-4b5e-9008-d986e7e3501e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05078866","created_at":"2021-10-15T15:53:08.571Z","updated_at":"2025-02-25T13:40:39.704Z","phase":"Phase 1/2","brief_title":"Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients","source_id_and_acronym":"NCT05078866","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOUS-209"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/10/2022","start_date":" 11/10/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-21"},{"id":"9ff75a13-e0fb-4659-a12b-a20b35ef7bb8","acronym":"FLAMINGO-01","url":"https://clinicaltrials.gov/study/NCT05232916","created_at":"2022-02-10T14:52:54.352Z","updated_at":"2025-02-25T13:40:51.671Z","phase":"Phase 3","brief_title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects","source_id_and_acronym":"NCT05232916 - FLAMINGO-01","lead_sponsor":"Greenwich LifeSciences, Inc.","biomarkers":" HER-2 • HLA-A","pipe":" | ","alterations":" HLA-A*02 positive","tags":["HER-2 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • GLSI-100 • GP2"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 08/11/2022","start_date":" 08/11/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"b8897926-0522-4fee-9673-a3eb75b62670","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173937","created_at":"2021-01-18T15:38:57.471Z","updated_at":"2025-02-25T13:39:29.284Z","phase":"Phase 1/2","brief_title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","source_id_and_acronym":"NCT03173937","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Omisirge (omidubicel)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 04/28/2025","primary_completion_date":" 04/28/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-21"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"0841b3a2-d056-4bdc-8db6-285dc71005a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02506933","created_at":"2021-01-18T12:06:04.560Z","updated_at":"2025-02-25T14:06:51.914Z","phase":"Phase 2","brief_title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","source_id_and_acronym":"NCT02506933","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Triplex (CMV-MVA vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"56170b22-f9c8-453b-b976-39bba6ed5d1e","acronym":"CIP2023-001","url":"https://clinicaltrials.gov/study/NCT06366490","created_at":"2024-04-16T20:48:26.282Z","updated_at":"2025-02-25T14:18:59.745Z","phase":"Phase 1","brief_title":"Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer","source_id_and_acronym":"NCT06366490 - CIP2023-001","lead_sponsor":"PhotonPharma, Inc.","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-17"},{"id":"f54e7e6b-bb69-4a1c-88ad-1174200e27c6","acronym":"IOV-EAP 402","url":"https://clinicaltrials.gov/study/NCT05398640","created_at":"2022-06-01T16:00:15.608Z","updated_at":"2025-02-25T14:17:00.566Z","phase":"","brief_title":"Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release","source_id_and_acronym":"NCT05398640 - IOV-EAP 402","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Amtagvi (lifileucel)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-17"},{"id":"24163a35-8b9c-475e-8999-ce9d118cb897","acronym":"SAKK 66/17","url":"https://clinicaltrials.gov/study/NCT03993678","created_at":"2021-01-18T19:38:09.158Z","updated_at":"2025-02-25T15:18:11.795Z","phase":"Phase 1/2","brief_title":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.","source_id_and_acronym":"NCT03993678 - SAKK 66/17","lead_sponsor":"Swiss Group for Clinical Cancer Research","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IP-001"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-12"},{"id":"e94eda48-02c6-40bc-8f38-bdeb553754b5","acronym":"CASE6119","url":"https://clinicaltrials.gov/study/NCT04674306","created_at":"2021-01-19T20:45:27.933Z","updated_at":"2025-02-25T15:18:56.819Z","phase":"Phase 1","brief_title":"Adjuvant Therapy with an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04674306 - CASE6119","lead_sponsor":"George T. Budd","biomarkers":" HER-2 • ER • PGR • BRCA1 • PRL","pipe":" | ","alterations":" HER-2 negative • PALB2 mutation • ER negative","tags":["HER-2 • ER • PGR • BRCA1 • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PALB2 mutation • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alpha-lactalbumin vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-12"},{"id":"4b6f2c6e-35f3-4b56-9b34-2f31c986974d","acronym":"BNT111-01","url":"https://clinicaltrials.gov/study/NCT04526899","created_at":"2021-01-18T21:40:45.863Z","updated_at":"2025-02-25T15:26:32.109Z","phase":"Phase 2","brief_title":"Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma","source_id_and_acronym":"NCT04526899 - BNT111-01","lead_sponsor":"BioNTech SE","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • BNT111"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 01/25/2024","primary_completion_date":" 01/25/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-10"},{"id":"8faa9c2f-7698-40c3-8644-3401597d3da2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05628883","created_at":"2022-11-29T15:57:45.457Z","updated_at":"2025-02-25T16:33:12.261Z","phase":"Phase 1","brief_title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05628883","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF • IL2","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TIDAL-01"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/22/2022","start_date":" 11/22/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-07"},{"id":"9034384d-853b-4bf5-b795-a33e0ba3054b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672355","created_at":"2023-01-05T14:58:31.435Z","updated_at":"2025-02-25T16:39:34.567Z","phase":"Phase 2","brief_title":"A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05672355","lead_sponsor":"City of Hope Medical Center","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 01/12/2026","primary_completion_date":" 01/12/2026","study_txt":" Completion: 01/12/2026","study_completion_date":" 01/12/2026","last_update_posted":"2025-02-06"},{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"e678f6ac-527c-48a1-b805-9ef0c833b79e","acronym":"IRB00210915","url":"https://clinicaltrials.gov/study/NCT04117087","created_at":"2021-01-18T20:07:26.907Z","updated_at":"2025-02-25T14:28:43.898Z","phase":"Phase 1","brief_title":"Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer","source_id_and_acronym":"NCT04117087 - IRB00210915","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • CD8 • CD4","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 08/08/2025","primary_completion_date":" 08/08/2025","study_txt":" Completion: 08/08/2025","study_completion_date":" 08/08/2025","last_update_posted":"2025-02-03"},{"id":"7e6819a5-0a0e-4ce4-b697-04b501a41ea6","acronym":"GT-30","url":"https://clinicaltrials.gov/study/NCT04251117","created_at":"2024-04-19T18:51:54.179Z","updated_at":"2025-02-25T17:24:31.308Z","phase":"Phase 1/2","brief_title":"GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC","source_id_and_acronym":"NCT04251117 - GT-30","lead_sponsor":"Geneos Therapeutics","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • rocakinogene sifuplasmid (INO-9012) • GNOS-PV02"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2028","study_completion_date":" 11/29/2028","last_update_posted":"2025-01-31"},{"id":"1ba644d9-46af-4d81-be0f-6a946f789cac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05539365","created_at":"2022-09-14T18:56:14.616Z","updated_at":"2025-02-25T17:38:04.297Z","phase":"Phase 2","brief_title":"Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer","source_id_and_acronym":"NCT05539365","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • aDC1 vaccine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-01-29"},{"id":"09038cde-7312-4363-a45d-ebec4e051166","acronym":"FusionVAC22_02","url":"https://clinicaltrials.gov/study/NCT06789198","created_at":"2025-02-25T17:54:08.734Z","updated_at":"2025-02-25T17:54:08.734Z","phase":"Phase 1","brief_title":"Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA","source_id_and_acronym":"NCT06789198 - FusionVAC22_02","lead_sponsor":"University Hospital Tuebingen","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA peptide vaccine • Fusion-VAC-XS15"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-01-28"},{"id":"0e159834-d55b-493f-b633-ada407fa2107","acronym":"KEYNOTE-603","url":"https://clinicaltrials.gov/study/NCT03313778","created_at":"2021-01-18T16:21:59.009Z","updated_at":"2025-02-25T16:07:00.519Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","source_id_and_acronym":"NCT03313778 - KEYNOTE-603","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK translocation • EGFR positive","tags":["EGFR • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK translocation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-22"},{"id":"f04191d0-49ef-4557-a5c3-c47df0794683","acronym":"","url":"https://clinicaltrials.gov/study/NCT06782932","created_at":"2025-02-25T19:18:04.732Z","updated_at":"2025-02-25T19:18:04.732Z","phase":"Phase 1/2","brief_title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","source_id_and_acronym":"NCT06782932","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-20"},{"id":"4a460451-5964-49e7-8b50-20d79d3f9b89","acronym":"HEMONC CIRM IST Lung","url":"https://clinicaltrials.gov/study/NCT03546361","created_at":"2021-01-18T17:27:35.511Z","updated_at":"2025-02-25T16:07:56.707Z","phase":"Phase 1","brief_title":"CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03546361 - HEMONC CIRM IST Lung","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ad-CCL21-DC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 01/11/2026","primary_completion_date":" 01/11/2026","study_txt":" Completion: 01/11/2027","study_completion_date":" 01/11/2027","last_update_posted":"2025-01-14"},{"id":"74a598bd-7a75-4999-b0f5-a6eb7255e5da","acronym":"NATASHA","url":"https://clinicaltrials.gov/study/NCT05325632","created_at":"2022-04-13T11:55:02.708Z","updated_at":"2025-02-25T13:54:21.396Z","phase":"Phase 2","brief_title":"Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab \u0026 Pertuzumab","source_id_and_acronym":"NCT05325632 - NATASHA","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • albumin-bound paclitaxel • HER-2 pulsed DC1"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-12-24"}]